SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

SciSparc Ltd. (Nasdaq: SPRC) announced the filing of an additional provisional patent application by Clearmind Medicine, focusing on the combination of Clearmind's MEAI and SciSparc's PEA for treating depression. This is part of a collaboration that has already seen three other patent applications filed for MEAI and PEA combinations targeting alcohol use disorder, cocaine addiction, and obesity. Furthermore, six more patents have been filed concerning PEA combined with various psychedelics including LSD and DMT. SciSparc aims to develop therapies for central nervous system disorders, with ongoing programs targeting Tourette Syndrome, Alzheimer's, pain, and autism spectrum disorder (ASD). With a focus on cannabinoid pharmaceuticals, the company is strategically positioned in the emerging psychedelic therapeutic market.

SciSparc Ltd. (NASDAQ: SPRC) has received final approval from the Tel Aviv Sourasky Medical Center for its Phase IIb Clinical Trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial will assess the drug's efficacy, safety, and tolerability in adults aged 18-65, using a randomized, double-blind, placebo-controlled method. The primary outcomes will be measured using the Yale Global Tic Severity Scale over 12 and 26 weeks. Prof. Tanya Gurevich will lead the trial at the Tel Aviv site, with additional trials planned at Yale University and Hannover Medical School, pending regulatory approvals.

SciSparc Ltd. (Nasdaq: SPRC) announced the closing of a sale of approximately 49% equity in its subsidiary, SciSparc Nutraceuticals Inc., to Jeffs’ Brands Holdings Inc. for a total of $2.5 million and additional payments of around $489,330. The new purchase price for the deal is approximately $3 million. SciSparc will hold around 51% of the subsidiary post-transaction. Under a consulting agreement, Jeffs' Brands will manage the subsidiary's Wellution™ brand for a monthly fee of $20,000, plus a signing bonus of $51,000. Wellution products have achieved significant success on Amazon with numerous positive reviews.

SciSparc Ltd. (Nasdaq: SPRC) announced on March 10, 2023, that it received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has until September 5, 2023, to regain compliance, with a grace period of 180 days to achieve this by maintaining the minimum bid price for at least ten consecutive business days. Failure to do so could lead to delisting, although an additional compliance period may be available if other listing requirements are met. Currently, there is no immediate effect on the company's Nasdaq listing, and shares will continue to trade under the symbol SPRC.

SciSparc Ltd. (NASDAQ: SPRC) announced that the Israeli Ministry of Health has granted approval for its clinical trial involving SCI-110, aimed at treating Tourette Syndrome (TS). The trial will take place at the Tel Aviv Sourasky Medical Center and includes international sites like Yale University and Hannover Medical School, pending regulatory approvals. The objective is to evaluate the efficacy, safety, and tolerability of SCI-110 in adults, utilizing a randomized, double-blind, placebo-controlled design. Prior Phase IIa results indicate potential benefits of SCI-110 for TS patients, which affects 0.5-1% of the global population.

SciSparc Ltd. (NASDAQ: SPRC) announced the successful manufacturing of clinical batches for its drug candidate SCI-110, intended for a Phase IIb trial targeting Tourette Syndrome. The manufacturing was done by Procaps Group under stringent Good Manufacturing Practices, ensuring compliance with FDA and European Medicines Agency standards. Ethics approvals have been secured from institutions in Germany and Israel, with plans to obtain further approval from Yale University. The trial aims to assess the efficacy and safety of SCI-110 in adults aged 18-65, following a randomized, placebo-controlled method. Successful trial outcomes could advance SciSparc's focus on cannabinoid pharmaceuticals.

SciSparc Ltd. (Nasdaq: SPRC) announced an agreement with Tikun Olam Cannbit Pharmaceuticals to supply CBD-rich oil for its proprietary SCI-210 treatment. This treatment, combining CBD and CannAmide™, will be evaluated in a clinical trial for children with autism spectrum disorder (ASD) at Soroka University Medical Center. The randomized, double-blind trial will assess safety, tolerability, and efficacy in 60 children over 20 weeks, utilizing key measures like the Aberrant Behavior Checklist-Community. The company received necessary approvals from the Israeli Ministry of Health and the Ethics Committee for the trial.